| pubmed-article:17717788 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17717788 | lifeskim:mentions | umls-concept:C1858460 | lld:lifeskim |
| pubmed-article:17717788 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:17717788 | lifeskim:mentions | umls-concept:C2349595 | lld:lifeskim |
| pubmed-article:17717788 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:17717788 | pubmed:dateCreated | 2008-8-18 | lld:pubmed |
| pubmed-article:17717788 | pubmed:abstractText | This article discusses the management of a pregnancy of a 32-year-old primigravida with acute myelocytic leukemia treated with induction chemotherapy starting in the 20 + 5 week of gestation. Sonographic monitoring showed evidence of fetal ascites and anemia that could be treated with an intrauterine fetal transfusion. After maternal recovery, a caesarean section was performed in the 27 + 5 week of gestation. We delivered a vivid eutrophic female prematurely. The infant showed persisting signs of myelosuppression. Two further transfusions had to be performed. The present report describes the interdisciplinary therapeutic management when polychemotherapy during pregnancy is necessary for the mother. Cases of acute leukemia in pregnancy are complicated by severe prenatal risks caused by the hematologic illness and by the immediate beginning of chemotherapy. In the third trimester premature delivery is preferable to intrauterine exposition to cytostatic agents. In the second trimester the pregnancy has to be monitored for the typical risks and complications of chemotherapy. Fetal cytotoxic myelosuppression is detectable by prenatal observation so that interventional strategies are feasible. | lld:pubmed |
| pubmed-article:17717788 | pubmed:language | ger | lld:pubmed |
| pubmed-article:17717788 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17717788 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17717788 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17717788 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:17717788 | pubmed:issn | 1438-8782 | lld:pubmed |
| pubmed-article:17717788 | pubmed:author | pubmed-author:GarnierYY | lld:pubmed |
| pubmed-article:17717788 | pubmed:author | pubmed-author:BakoFF | lld:pubmed |
| pubmed-article:17717788 | pubmed:author | pubmed-author:HoopmannMM | lld:pubmed |
| pubmed-article:17717788 | pubmed:author | pubmed-author:EifingerFF | lld:pubmed |
| pubmed-article:17717788 | pubmed:author | pubmed-author:RahimiGG | lld:pubmed |
| pubmed-article:17717788 | pubmed:author | pubmed-author:HartlappII | lld:pubmed |
| pubmed-article:17717788 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17717788 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:17717788 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17717788 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17717788 | pubmed:pagination | 424-7 | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:meshHeading | pubmed-meshheading:17717788... | lld:pubmed |
| pubmed-article:17717788 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:17717788 | pubmed:articleTitle | [Chemotherapy-induced fetal anemia in maternal acute myelocytic leukemia]. | lld:pubmed |
| pubmed-article:17717788 | pubmed:affiliation | Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Köln. markus.hoopmann@uk-koeln.de | lld:pubmed |
| pubmed-article:17717788 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17717788 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:17717788 | pubmed:publicationType | Case Reports | lld:pubmed |
